Skip to main content

Table 3 Univariate analysis of risk factors for the survival of ACLF patients

From: Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure

Related factors Survivor (n = 76) (Mean ± SD) Non-survivor (n = 55) (Mean ± SD) t or χ 2 value P value
Male (%) 64 (84.21) 47 (85.45) 0.04 0.85
HBeAg positive (%) 19 (25.00) 18 (32.73) 0.94 0.33
Treatment without NAs (%) 30 (39.47) 40 (72.73) 14.18 <0.001
Age (yr) 39.49 ± 10.50 45.05 ± 9.96 3.06 0.003
HBV DNA log10 (copies/ml) 5.52 ± 1.40 5.50 ± 1.60 0.08 0.94
TBIL (μmol/L) 271.33 ± 111.05 265.23 ± 122.78 0.30 0.77
Albumin (g/L) 34.67 ± 5.44 34.34 ± 4.77 0.37 0.71
ALT (U/L) 912.92 ± 861.61 950.50 ± 744.03 0.26 0.80
PTA (%) 33.81 ± 9.40 30.21 ± 10.50 2.05 0.042
Creatinine (μmol/L) 66.66 ± 14.74 79.03 ± 57.78 1.55 0.13
MELD Score 22.11 ± 2.84 25.24 ± 6.19 3.49 0.001